Celsion (NASDAQ:CLSN) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Celsion (NASDAQ:CLSNGet Rating) in a report issued on Wednesday morning. The firm issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright initiated coverage on Celsion in a report on Wednesday, April 13th. They issued a buy rating and a $16.00 target price for the company.

NASDAQ:CLSN opened at $3.02 on Wednesday. The firm has a market cap of $17.43 million, a PE ratio of -0.77 and a beta of 2.11. The stock has a fifty day moving average price of $4.73 and a 200 day moving average price of $8.15. Celsion has a 12-month low of $3.00 and a 12-month high of $23.25. The company has a current ratio of 7.67, a quick ratio of 7.67 and a debt-to-equity ratio of 0.10.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Jane Street Group LLC lifted its holdings in Celsion by 181.8% during the 3rd quarter. Jane Street Group LLC now owns 36,055 shares of the biotechnology company’s stock worth $33,000 after buying an additional 23,261 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Celsion by 7.8% during the third quarter. Geode Capital Management LLC now owns 756,885 shares of the biotechnology company’s stock worth $699,000 after purchasing an additional 54,785 shares in the last quarter. FNY Investment Advisers LLC acquired a new stake in shares of Celsion during the fourth quarter worth about $35,000. Two Sigma Advisers LP acquired a new stake in shares of Celsion during the third quarter worth about $68,000. Finally, Virtu Financial LLC acquired a new stake in shares of Celsion during the fourth quarter worth about $55,000. 10.75% of the stock is owned by institutional investors.

About Celsion (Get Rating)

Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications.

See Also

Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.